MET

advanced non-squamous NSCLC (6 products)

MET exon 14 skipping NSCLC (6 products)

EGFR-mutated, c-Met overexpressing NSCLC (4 products)

EGFRm+ NSCLC with CNS metastasis (3 products)

EGFR-mutated advanced NSCLC with atypical mutations (3 products)

EGFR ex20ins-mutant NSCLC (3 products)

NSCLC with high-level MET amplification (3 products)

NSCLC with EGFR mutations and ALK rearrangements with brain metastases (2 products)

advanced EGFR-mutated NSCLC (2 products)

glioblastoma (2 products)

metastatic non-small cell lung cancer (2 products)

MET-altered advanced non-small cell lung cancer (2 products)

Advanced NSCLC with EGFR mutation (2 products)

NSCLC with EGFR exon 19 deletion or L858R (1 products)

NSCLC with other uncommon non-ex20ins EGFR mutations (1 products)

NSCLC with EGFR exon 20 insertion mutations (1 products)

KRAS G12C mutant NSCLC (1 products)

Locally advanced/metastatic c-Met overexpressing EGFR WT nonsquamous NSCLC (1 products)

Non-squamous EGFR wildtype NSCLC with c-Met protein overexpression (1 products)

urothelial carcinoma (1 products)

Metastatic Castration-Resistant Prostate Cancer (1 products)

advanced clear cell renal cell carcinoma (ccRCC) (1 products)

advanced HRD high-grade ovarian cancer (1 products)

Metastatic renal cell carcinoma with sarcomatoid differentiation (1 products)

advanced urothelial carcinoma (1 products)

recurrent or metastatic head and neck squamous cell carcinoma (1 products)

metastatic melanoma (1 products)

Advanced non-small cell lung cancer with actionable driver oncogenes (1 products)

metastatic hormone sensitive prostate cancer (1 products)

Stage III melanoma (1 products)

ALK-rearrangement positive NSCLC (1 products)

ROS1-rearranged NSCLC (1 products)

Non-Small Cell Lung Cancer (1 products)

EGFR-mutant, T790M−, MET-amplified NSCLC (1 products)